key: cord-0919364-cqfoqact
authors: Moskowitz, Ari; Shotwell, Matthew S.; Gibbs, Kevin W.; Harkins, Michelle; Rosenberg, Yves; Troendle, James; Merck, Lisa H.; Files, D. Clark; de Wit, Marjolein; Hudock, Kristin; Thompson, B. Taylor; Gong, Michelle N.; Ginde, Adit A.; Douin, David J.; Brown, Samuel M.; Rubin, Eileen; Joly, Meghan Morrison; Wang, Li; Lindsell, Christopher J.; Bernard, Gordon R.; Semler, Matthew W.; Collins, Sean P.; Self, Wesley H.
title: Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New Onset Hypoxemia
date: 2022-04-30
journal: Chest
DOI: 10.1016/j.chest.2022.04.145
sha: 2d67a3d735234d13d01e707669fc72408649cc59
doc_id: 919364
cord_uid: cqfoqact

Mortality has historically been the primary outcome of choice for acute and critical care clinical trials. However, undue reliance on mortality can limit the scope of trials that can be performed. Large sample sizes are usually needed for trials powered for a mortality outcome and focusing solely on mortality fails to recognize the importance that reducing morbidity can have patients’ lives. The coronavirus disease 2019 (COVID-19) pandemic has highlighted the need for rapid, efficient trials to rigorously evaluate new therapies for hospitalized patients with acute lung injury. Oxygen-free days (OFDs) is a novel outcome for clinical trials that is a composite of mortality and duration of new supplemental oxygen use. It is designed to characterize recovery from acute lung injury in populations with a high prevalence of new hypoxemia and supplemental oxygen use. In these populations, OFDs captures two patient-centered consequences of acute lung injury, including mortality and hypoxemic lung dysfunction. Power to detect differences in OFDs is typically greater than that for other clinical trial outcomes such as mortality and ventilator-free days. OFDs is the primary outcome for the ACTIV-4 Host Tissue platform, which evaluates novel therapies targeting the host response to COVID-19 among adults hospitalized with COVID-19 and new hypoxemia. This manuscript outlines the rationale for use of OFDs as an outcome for clinical trials, proposes a standardized method for defining and analyzing OFDs, and provides a framework for sample size calculations using the OFD outcome.

J o u r n a l P r e -p r o o f

Mortality has historically been the primary outcome of choice for acute and critical care clinical 164 trials. However, undue reliance on mortality can limit the scope of trials that can be performed. 165

Large sample sizes are usually needed for trials powered for a mortality outcome and focusing 166 solely on mortality fails to recognize the importance that reducing morbidity can have patients' 167 lives. The coronavirus disease 2019 (COVID-19) pandemic has highlighted the need for rapid, 168 efficient trials to rigorously evaluate new therapies for hospitalized patients with acute lung 169 injury. Oxygen-free days (OFDs) is a novel outcome for clinical trials that is a composite of 170 mortality and duration of new supplemental oxygen use. It is designed to characterize recovery 171 from acute lung injury in populations with a high prevalence of new hypoxemia and 172 supplemental oxygen use. In these populations, OFDs captures two patient-centered 173 consequences of acute lung injury, including mortality and hypoxemic lung dysfunction. Power 174 to detect differences in OFDs is typically greater than that for other clinical trial outcomes such 175 as mortality and ventilator-free days. OFDs is the primary outcome for the ACTIV-4 Host Tissue 176 platform, which evaluates novel therapies targeting the host response to COVID-19 among 177 adults hospitalized with COVID-19 and new hypoxemia. This manuscript outlines the rationale 178 for use of OFDs as an outcome for clinical trials, proposes a standardized method for defining 179

Mortality has historically been the primary outcome of choice for efficacy trials evaluating 183 interventions for acute respiratory failure and other severe acute medical conditions. 1 While 184 decreasing the incidence of mortality is clearly an important and patient-centered goal, the 185 selection of mortality as a primary outcome has limitations including: 1) the potential for missing 186 an important efficacy signal for reduced morbidity; 2) large sample sizes needed for adequate 187 power to detect important differences in mortality; and 3) interventions under study may only 188 impact specific pathways toward death, while acutely ill patients often have many potential 189 causes of death that may not be attributable to the intervention. 2,3 190

Days alive and free of a supportive therapy ("free-day" outcomes) provide an alternative 191 to mortality as a primary outcome in clinical trials of therapies targeted at acute respiratory 192 distress syndrome (ARDS), sepsis, and other severe illnesses. 2,4,5 Free-day outcomes combine 193 mortality with clinically relevant morbidities (e.g., days on ventilator support 6 , days on 194 vasopressor support 7 , days in the hospital 8 ), creating composite outcomes reflective of both 195 morbidity and mortality. Free-day outcomes are typically analyzed as ordinal variables and can 196 permit trials with smaller sample sizes to identify clinically meaningful differences in patient 197

The coronavirus disease 2019 (COVID-19) pandemic has revealed a further need for 199 patient-centered outcomes that facilitate efficient, rapid trials of promising therapies for patients 200 with acute lung injury. Due to its widespread morbidity and mortality, the COVID-19 pandemic 201 requires rapid identification of efficacious therapies and equally rapid abandonment of therapies 202 with a low likelihood of efficacy. Thus, the pandemic demands both efficiency and rigor in 203 clinical trial design. Using patient-centered, non-mortal primary outcomes is one method of 204 improving clinical trial efficiency. While several non-mortal outcomes for COVID-19 trials have 205 been used, including time to recovery 9 , clinical status scores 10 , and sustained recovery 11,12 , 206 none has been universally adopted. 207 J o u r n a l P r e -p r o o f Most patients admitted to the hospital with COVID-19 experience mild-to-moderate lung 208 injury, are treated with supplemental oxygen via nasal cannula on hospital wards, and do not 209 progress to invasive mechanical ventilation or death. [13] [14] [15] [16] In this setting, wherein death, invasive 210 mechanical ventilation and other organ support therapies are rare, a composite outcome that 211 includes death and oxygen use may capture the key disease-related acute mortality and 212 morbidity of interest. Oxygen-free days (OFDs), a composite ordinal outcome that includes 213 mortality and duration of supplemental oxygen use, has been employed as a key outcome 214 measure in trials of COVID-19 10,17 and other acute diseases. 18 OFDs also serves as the primary 215 outcome in a new platform trial evaluating host response therapies among adults hospitalized 216 with COVID-19-associated lung injury-the fourth Accelerating COVID-19 Therapeutic 217

Interventions and Vaccines (ACTIV-4) Host Tissue trial (NCT# 04924660). In this manuscript, 218

we discuss the rationale for selecting OFDs as the primary outcome in the ACTIV-4 Host Tissue 219 trial, propose a standard definition for OFDs, outline an approach to analyzing OFDs, and 220 demonstrate sample size calculations for OFDs using data from a recently completed COVID-19 221 trial. 17 222 223

The OFD outcome is modeled after the ventilator-free days outcome, a composite of duration of 225 invasive mechanical ventilation and death. Ventilator-free days is an established outcome 226 measure in trials of critically ill patients receiving invasive mechanical ventilation. 6,19-22 227

Ventilator-free days was developed based on the notion that trials powered only on mortality 228 frequently require very large sample sizes (or often a sacrifice in scientific rigor) and therapies 229 that reduce the duration of mechanical ventilation can produce meaningful improvements in Previous work has emphasized that clinical trial outcomes should be: 1) important to the 242 patient, 2) potentially modifiable by the intervention under investigation, and 3) reliably 243 measurable. 24 In this section, we review how the OFDs outcome meets each of these criteria. 

For OFDs to be an optimal trial outcome, the control group must experience a substantial 272 burden of supplemental oxygen use in the 28 days following randomization and the therapies 273 under investigation must target mechanistic pathways expected to lessen or resolve hypoxemia. 274

In the ACTIV-4 Host Tissue platform, all enrolled patients are hospitalized with COVID-275 19 and hypoxemia (SpO2 <92% on room air for patients without chronic supplemental oxygen 276 use or a supplemental oxygen flow rate higher than baseline for patients on chronic oxygen 277 therapy). Thus, nearly all trial participants are receiving supplemental oxygen therapy at 278 randomization. In this context, OFDs measures the time to lung recovery (defined as liberation 279 from supplemental oxygen therapy) among patients with COVID-19-associated hypoxemia, with 280 an appropriate penalty for mortality. Interventions hastening lung recovery, therefore, should 281 increase the number of oxygen free days. OFDs is highly applicable to all patients enrolled in 282 ACTIV-4 Host Tissue. In contrast, ventilator-free days would likely fail to capture a substantial 283 amount of lung recovery, because a majority of patients with COVID-19 hospitalized with 284 hypoxemia never progress to invasive mechanical ventilation. 16 Lung injury treated with non-285 J o u r n a l P r e -p r o o f invasive oxygen (e.g. nasal cannula) would be completely missed by a ventilator-free day 286 outcome and practice differences in intubation threshold may introduce noise to the outcome 287 without reflecting recovery. Further, the distribution of ventilator-free days would be highly 288 bimodal, with a peak at -1 for mortality and at 28 for patients who never progressed to invasive 289 mechanical ventilation. By contrast, as detailed below, the distribution of OFDs is highly 290 dispersed across the entire continuum from -1 to 28 days. 291

The first three therapies being evaluated on the ACTIV-4 Host Tissue platform are TXA-292 127 (Constant Therapeutics) 30 , TRV-027 (Trevena) 31 , and fostamatinib (Rigel 293 Pharmaceuticals) 32 . These therapies are compared to placebo in a randomized, blinded 294 platform trial. Each of these therapies is hypothesized to improve lung function for hypoxemic 295 patients with COVID-19. Thus, the measurement of OFDs should capture the key beneficial 296 effects hypothesized to occur with each therapy. A separate protocol and statistical analysis 297 plan will be published with additional details of the therapies under investigation. 298 299 Can OFDs be reliably and accurately measured in clinical trials? 300

As detailed in the next section, the data needed to calculate OFDs is reliably captured via 301 medical record abstraction and simple questions posed to patients during post-discharge follow-302 up visits. Thus, OFDs can be ascertained with standard methods routinely used in clinical trials 303 and without the need for in-person visits after discharge. 304 305

No universally accepted definition for OFDs exists. To facilitate comparisons across trials, a 307 standardized definition for OFDs will be important. In this section, we outline the definition of 308

OFDs being used in the ACTIV-4 Host Tissue platform as a paradigm for how the measurement 309 of OFDs may be standardized. 310

OFDs is a composite ordinal outcome incorporating death and duration of supplemental 311 oxygen use onto the same scale, with death coded as the worst possible outcome. A follow-up 312 period of 28 days for ascertaining OFDs is being used in the ACTIV-4 Host Tissue platform 313 based on precedent in the field for measuring morbidity and mortality in acute care trials 20-22 , 314 and recent data from COVID-19 studies demonstrating that approximately 75% of hospitalized 315 patients with COVID-19 treated with new oxygen therapy have died or been liberated from 316 oxygen by day 28. 17 However, the duration of follow-up can be modified to fit priorities. For 317 example, it may be preferable to extend the follow-up period to 60 or 90 days for trials of 318 patients with more persistent acute lung injury or those evaluating patients with chronic lung 319 disease. 320

Using a 28-day follow-up period, OFDs is calculated as the number of calendar days 321 during the first 28 days after randomization during which the patient was alive and not receiving 322 The day of randomization is day 0. Starting with calendar day 1 (the day after randomization) 329

and continuing for 28 days, oxygen use is ascertained daily, with any duration of oxygen use on 330 a calendar day designating that day as an oxygen use day (i.e., not an oxygen-free day). OFDs 331 is calculated using a first on/ last off methodology. All days between the first initiation of oxygen 332 use and the last liberation from oxygen use are classified as oxygen use days. As an example, if 333 a patient is weaned off oxygen for a day but then is reinitiated on oxygen the following day, the 334 single day without oxygen use between two days with oxygen use is not considered an oxygen-335 free day. This first on/last off approach is used so that the outcome captures the final liberation 336 J o u r n a l P r e -p r o o f of supplemental oxygen therapy, which is considered more clinically meaningful than transient 337 pauses in oxygen therapy. 338

Patients who chronically used supplemental oxygen prior to their acute illness are 339 considered oxygen free when they return to the same level of oxygen support they had been 340 using prior to their acute illness. For example, a patient who chronically used supplemental 341 oxygen at 4 liters per minute via nasal cannula before the acute illness and then had escalation 342 of oxygen use during the illness would be considered oxygen free when he/she returned to 343 oxygen support via nasal cannula at 4 liters per minute or less. For the calculation of OFDs, a patient who dies before day 28 (either in the hospital or 355 after discharge) is coded as having -1 oxygen free days regardless of the number of days of 356 oxygen use prior to death. Hence, OFDs is an ordinal outcome with 30 possible levels (range: -1 357 to 28). The ordinal levels are ordered so that lower numbers indicate a worse outcome (Table  358 1). However, the difference between levels is not implied to be equal across the scale. For 359 example, the clinical difference between death (-1 OFDs) and 0 oxygen free days is not the 360 same as the difference between 10 OFDs and 11 OFDs. After their original introduction into 361 clinical trials, free-day outcomes often coded death as "0". 3 More recently, and consistent with 362 J o u r n a l P r e -p r o o f the approach outlined here, investigators have been coding death as -1 to distinguish death 363 from organ support for the full follow-up period. 4, 5, 23, 33 This is especially important for OFD, 364

where ongoing oxygen need at the end of the follow-up period is likely to be a far preferable 365 option to death. 366

As with all composite outcomes, it is important to report results for each component of 367

OFDs-duration of oxygen use in survivors and 28-day mortality-to clearly present trial 368 findings. 369 370

During the COVID-19 pandemic, several outcomes for trials evaluating in-hospital therapies 372 have been advanced as investigators sought to capture the key patient-centered concepts that 373

Progression ordinal scale has been used as a primary outcome in several trials. 34 This scale, 375 initially conceived to track the progress of COVID-19 patients through the healthcare system, 376 has a number of strengths and is a recommended outcome measure for respiratory failure in 377 COVID-19 core outcome sets. 35 It is composed of mortality and levels of respiratory support. It 378 is broadly applicable to the full range of COVID-19 disease severity, is relatively simple to 379 measure, and can be easily abstracted from medical records. However, the WHO Clinical 380

Progression scale has limitations. Although the scale may be measured serially and analyzed 381 with longitudinal models, it is typically used to measure clinical status at a discrete cross-382 sectional point in time, such as at 14 days or 28 days after randomization. This is not consistent 383 with how lungs recover from acute injury, which is usually a gradual process that occurs over 384 weeks. One advantage of OFDs is that it captures lung recovery over the entire 28-day follow-385 up period, enabling a more detailed characterization of lung recovery over time. Comparison of 386 Table 2 . 387

The concept of time to liberation from oxygen therapy has also been extensively used 388 within "time to recovery" outcomes. For example, the primary outcome for the first Adaptive 389 COVID-19 Treatment Trial (ACTT-1) was 'time to recovery,' defined as time between 390 randomization and the earlier of hospital discharge or discontinuation of oxygen therapy and 391 other in-hospital therapies for Weaknesses of time to recovery as an outcome 392 include the competing risk of death, which is not incorporated into the outcome, and the 393 truncation of outcome assessment at hospital discharge. Limiting outcome ascertainment to the such that OFDs demonstrates an overall benefit despite higher mortality in the intervention 426 group. To safeguard against such a scenario, investigators can specify that OFDs will only be 427 used to support the efficacy of an intervention if mortality is not significantly worse in the 428 intervention group compared to the control group. 429

Importantly, OFDs are a better reflection of illness duration as opposed to peak illness 430 severity. For instance, a patient who is treated with invasive mechanical ventilation and a total 431 duration of oxygen use for 14 days will have the same number of OFDs as a patient who is 432 treated with supplemental oxygen by nasal cannula for 14 days despite the first patient having 433 higher peak severity of illness. That OFDs do not fully reflect illness severity has implications 434 both for statistical power (i.e., some information is lost regarding the potential impact of an 435 intervention by not differentiating the duration of different intensities of respiratory support) and 436

for the patient centeredness of the outcome as individuals would likely prefer to avoid a period 437 of more invasive support even if the overall duration was similar. Alternative outcomes that 438 incorporate both duration of oxygen support and illness severity using a ranking system are 439 technically possible, however would be substantially more complex and could be difficult to 440 interpret from a clinical perspective. Secondary outcomes assessing peak illness severity can 441 be used to complement OFDs and attenuate the above concerns. 442 443

In the ACTIV-4 Host Tissue platform, OFDs will be analyzed as an ordinal outcome with 30 445 possible levels (range: -1 to 28 days). The number of OFDs in intervention and control groups 446 will be summarized with histograms, medians values, and interquartile ranges. The primary 447 analysis will be conducted using a proportional odds model comparing the distribution of OFDs 448 in an intervention group versus a concurrent placebo group. This method is appropriate for 449 ordinal outcomes, like OFDs, where the levels are ordered but the relative differences between 450 levels are not defined. The statistical model includes covariates for key baseline characteristics, 451

including age, sex, and WHO COVID-19 ordinal score. The model produces an odds ratio that 452 represents the covariate-adjusted effect of intervention on the odds of greater OFDs for a 453 participant in the active group compared with the placebo group. For example, an adjusted odds 454 ratio of 1.2 means that a participant has 20% greater odds in the intervention group compared 455 with the control group of having more than "X" OFDs. The proportional odds assumption means 456 this interpretation applies for each possible value "X". An adjusted odds ratio >1.0 indicates a 457 greater number of oxygen free days (benefit) in the active group compared to the placebo 458 group. In the event the proportional odds assumption is violated, the estimated odds ratios 459 remain interpretable and reflect a global assessment of treatment effectiveness. Alternative 460 methods, such as 0-1 inflated beta-binomial regression, may also be used for modeling the 461 distribution of OFDs. The method used to simulate treatment effects using the proportional odds 

While the minimum clinically important difference in OFDs has not been definitively described, 476 using a detectable difference of about 2 OFDs for sample size calculations is consistent with 477 approaches used for other free-day and time to recovery outcomes 21,22 and expert opinion on 478 meaningful changes in duration of organ support. 36 Table 3 shows the relationship between 479 differences in OFDs in an intervention group and control group and the odds ratio generated 480 from a proportional odds model based on PassITON data. An odds ratio of 1.55 corresponds to 481 a mean difference of 2.3 OFDs (16.8 OFDs in the placebo group and 19.1 OFDs in the 482 intervention group), including a 5.5% absolute reduction in mortality (17.6% mortality in the 483 placebo group and 12.1% mortality in the intervention group). 484

Power calculations for the ACTIV-4 Host Tissue platform were conducted using these 485 data from PassITON. Enrollment of 300 participants in an intervention group and 300 patients in 486 a placebo group (600 total participants) provides 85% power to detect an odds ratio of 1.55 for 487

OFDs. Thus, each treatment arm in the ACTIV-4 Host Tissue platform will target 300 488 participants per group. Detection of odds ratios of 1.40 (difference of 1.8 OFDs), 1.45 489 (difference of 2.0 OFDs), and 1.50 (difference of 2.2 OFDs) with 85% power would require 510, 490 392, and 346 participants per group, respectively. 491

Power to detect clinically meaningful changes was substantially higher for OFDs than for 492 ventilator-free days and mortality. The distribution of ventilator-free days in PassITON is shown 493

in Figure 2b , demonstrating reduced variability and a higher proportion of the population 494 experiencing 28 free days compared to OFDs. An odds ratio of 1.55 in PassITON corresponded 495 to approximately a mean 2.1-day improvement in ventilator-free days. A sample size of 300 496 participants per group provided 72% power to detect an odds ratio of 1.55 for ventilator-free 497 days. For a 28-day mortality dichotomous outcome, 300 participants per group provided 47% 498 power to detect a 5.5% absolute difference in mortality between the intervention and control 499 groups. 500 501

OFDs is an emerging clinical trials outcome that is a composite of mortality and duration of new 503 supplemental oxygen use. It is designed to characterize recovery from acute lung injury in 504 populations with a high prevalence of supplemental oxygen use and relatively low prevalence of 505 invasive mechanical ventilation. In these populations, OFDs captures key patient-centered 506 consequences of acute lung injury (including mortality and clinically meaningful lung 507 dysfunction) and increases statistical power to detect meaningful differences. OFDs is an 508 important addition to the set of outcome measures that investigators can use to characterize a 509 patient's course of acute lung injury and for evaluating therapies aimed at improving morbidity 510 and mortality for these patients. 1 Patient survived through day 28 and was free from oxygen use for 1 day in the first 28 days following randomization.

10 Patient survived through day 28 and was free from oxygen use for 10 days in the first 28 days following randomization.

Patient survived through day 28 and was free from oxygen use for 25 days in the first 28 days following randomization.

Patient survived through day 28 and was free from oxygen use on every calendar day from Day 1 to Day 28.

J o u r n a l P r e -p r o o f use after hospital discharge for the calculation of oxygen free days for patients not on oxygen at 627 baseline (before the acute illness). For patients who did use oxygen at baseline, similar 628 questions are asked to ascertain oxygen use above baseline. These questions are asked by 629

telephone, text message, or another telecommunication method during study visits after the 630 patient has been discharged from the hospital. Answers to these questions are used to 631 understand if the patient used oxygen after hospital discharge, and if so, when the final 632 liberation from oxygen occurred. Patient is off oxygen. Reassess oxygen use at next visit to evaluate if oxygen was restarted before next visit.

Is the patient still using oxygen at least some every day?

On what day did the patient last use oxygen?

Patient remains on oxygen.

Reassess oxygen use at next visit to evaluate if oxygen was stopped before next visit. Record date of last oxygen use Patient is off oxygen. Reassess oxygen use at next visit to evaluate if oxygen was restarted before next visit. Being on oxygen also affected me mentally, cognitively, as well. Once I was oxygen free, I was able to comprehend everything to a greater degree. My nurse described it as if a cloud was removed from my brain suddenly. I was reading medical articles about what ARDS was once I was oxygen free but prior to that, I refused to even read a People magazine or the daily newspaper.

Therefore, coming off of oxygen affects patients both physically and mentally in a number of ways. It also affects how they view their own recovery and progress. It has implications with respect to insurance issues and expenses. And it affects patients in terms of getting back to a point of returning to their health as it existed before they got ill, both socially and with respect to employment. It certainly affects their quality of life as well."

J o u r n a l P r e -p r o o f e- Figure 1 . The effect of treatment (OR = 1.5; = log(1.5)) on the outcome category probabilities for a hypothetical 11-level ordinal outcome, where the control group probabilities come from the Poisson distribution with parameter = 5. An odds ratio greater than one increases the probability Pr( > | ) for all thresholds . Thus, the distribution of the outcome is shifted toward the right.

The R script below reproduces the figure above and demonstrates a simple process for randomly generating ordinal outcome data in hypothetical control and treatment groups (OR=1.5), and then analyzing the effect of treatment using proportional odds regression. In this single simulation, with 100 simulated outcomes per group, the estimated treatment effect is OR = 1.97 ( = 0.6756; see last line of script output below beginning with "group=Treatment").

library('ggplot2') library('dplyr') library('rms') ## logit and expit functions logit <-function(p) log(1/(1/p-1)) expit <-function(x) 1/(1/exp(x) + 1) 

Early Neuromuscular Blockade in the Acute Respiratory 513 Distress Syndrome

Reappraisal of Ventilator-Free 515 Days in Critical Care Research

Statistical evaluation of ventilator-free days as an efficacy measure 518 in clinical trials of treatments for acute respiratory distress syndrome

Therapeutic Anticoagulation with Heparin in 521 Critically Ill Patients with Covid-19

Therapeutic Anticoagulation with Heparin in 524 Noncritically Ill Patients with Covid-19

Comparison of two fluid-management strategies 527 in acute lung injury

Effect of Selepressin vs

Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial

Balanced Crystalloids versus Saline in Noncritically Ill 532 Adults

Remdesivir for the Treatment of Covid-19 -Final Report

Effect of Hydroxychloroquine on Clinical Status at 14 536 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 541 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

MMWR Morb Mortal Wkly Rep

Characteristics of and Important Lessons From the Coronavirus Disease 547 2019 (COVID-19) Outbreak in China

Disease Control and Prevention

Epidemiology, clinical course, and outcomes of 550 critically ill adults with COVID-19 in New York City: a prospective cohort study

Association Between mRNA Vaccination and COVID-19 553 Hospitalization and Disease Severity

Passive Immunity Trial for Our Nation (PassITON): study 556 protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in 557 hospitalized adults

A multicenter cluster randomized, stepped wedge 559 implementation trial for targeted normoxia in critically ill trauma patients: study protocol and statistical 560 analysis plan for the Strategy to Avoid Excessive Oxygen (SAVE-O2) trial. Trials

Effect of Dexamethasone on Days Alive and 563 Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-564 19: The CoDEX Randomized Clinical Trial

Effect of a Low vs Intermediate Tidal Volume 567 Strategy on Ventilator-Free Days in Intensive Care Unit Patients Without ARDS: A Randomized Clinical 568

Effect of Vitamin C, Thiamine, and Hydrocortisone on 570

Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial

Conservative Oxygen Therapy during Mechanical 573 Ventilation in the ICU

Alive and Ventilator Free: A Hierarchical, Composite 575 Outcome for Clinical Trials in the Acute Respiratory Distress Syndrome

Outcome measures for clinical research in sepsis: a 578 report of the 2nd Cambridge Colloquium of the International Sepsis Forum

Contemporary strategies to improve clinical trial design 581 for critical care research: insights from the First Critical Care Clinical Trialists Workshop

Burden and Unmet Needs with Portable Oxygen in Patients on 584 Long-Term Oxygen Therapy

Home Oxygen Therapy for Adults with Chronic Lung 587

An Official American Thoracic Society Clinical Practice Guideline

Patients Choose Hypoxemia over Social Isolation

After hospitalizations, COVID-19 patients need oxygen

Effect of Titrating Positive End-Expiratory 597

Pressure (PEEP) With an Esophageal Pressure-Guided Strategy vs an Empirical High PEEP-Fio2 Strategy 598 on Death and Days Free From Mechanical Ventilation Among Patients With Acute Respiratory Distress 599 Syndrome: A Randomized Clinical Trial

Core Outcome Measures for Trials in People With 603

Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery

What change in outcomes after cardiac arrest is necessary 606 to change practice? Results of an international survey. Resuscitation

Input from Eileen Rubin, an ARDS survivor and current president of the ARDS Foundation (ardsglobal.org), on the use of supplemental oxygen therapy during recovery from ARDS. These statements were expressed to the ACTIV-4 Host Tissue investigators on January 10, 2022."Supplemental oxygen is definitely an indicator of illness severity as well as recovery. Supplemental oxygen affects patients in the hospital. It does create longer lengths of stay in the hospital and affects how patients gauge their progress and recovery. Requiring oxygen is a burden to patients both in the hospital and also if required at home. It is also a burden to caregivers. Upon being released from the hospital, setting up the requirements of oxygen at home necessitates logistics by patients and/or caregivers. There may be added expense to patients if insurance does not cover the new expenses.This can also create fear for patients who suddenly require oxygen at home, which affects a patient's quality of life. Suddenly a patient has to trust in an outside agency to provide their oxygen, which the patient requires for their health and life, to survive.It also affects how well a patient views their recovery of their illness. As they require oxygen longer, they view themselves as not improving or getting better. Plus, oxygen often creates selfimposed restrictions on patients, as some patients will become homebound rather than go out with oxygen.It also creates difficulties, both in the hospital, and at home, with early mobility, which I will address related to my hospitalization below.When I was being weaned from the vent, I was always aware of how much oxygen I was receiving and related it to the severity of my illness and this affected my desire to fight my illness. (I was in a medically induced coma for four weeks, on the vent for a total of eight weeks, and in the hospital for nine weeks.) I was constantly worried that the tubing would disconnect from my trach and I would die.

The proportional odds (PO) model is written in terms of the covariates and ordinal outcome , where the probability that takes a value or smaller is Pr( ≤ | ) = expit(α − β), where α is the intercept for outcome value and expit is the inverse logit transformation:If represents the treatment/control indicator (i.e., = 0 for all participants that are assigned the control condition, and = 1 for all participants that are assigned the treatment condition), then β represents the log of the odds ratio (OR) associated with treatment versus control. Specifically, the treatment/control odds ratio represents the relative effect of treatment on the odds Pr( > | ) (1 − Pr( > | )) ⁄ , for any value . In other words, when β is positive (i.e., OR > 1), then higher values of are more likely in the intervention group.If there are preliminary data regarding the ordinal outcome in the control group, those data may be used to estimate the probability of each ordinal category (i.e., when = 0 ) using the sample proportions. Denote these proportions , then the corresponding intercept estimates are as follows:A postulated treatment effect may then be combined with the intercepts, using the PO model expression above, = − , and the corresponding ordinal category probabilities for the treatment group are recovered as follows: 

c(expit(a[1]), diff(c(expit(a),1))) ## specify a treatment effect (OR = 1.5) beta <-log(1.5)

y_levels <-0:10 p_c <-dpois(y_levels, lambda=5)

## compute category probabilities for treatment group p_t <-alphs_to_probs(alpha_t)

rbind(data.frame(group = 'Control', level=y_levels, probs = p_c), data.frame(group = 'Treatment', level=y_levels, probs = p_t)) %>% ggplot(aes(x=level, y=probs, group=group, fill=group)) + geom_bar(stat = 'identity', position='dodge') + labs(x="Outcome category", y="Probability", fill="") + theme_minimal() + theme(legend.position = 'top') + scale_x_continuous(breaks=y_levels) ## simulate samples from the control and treatment groups n_per_group <-100 control_outcomes <-sample(y_levels, size=n_per_group, replace=TRUE, prob=p_c) treatment_outcomes <-sample(y_levels, size=n_per_group, replace=TRUE, prob=p_t) data <-data.frame( group = rep(c('Control','Treatment'), rep(n_per_group,2)), outcome = c(control_outcomes, treatment_outcomes)) ## compare the groups using proportional odds logistic regression rms::lrm(outcome ~ group, data=data) ## Logistic Regression Model ## ## rms::lrm(formula = outcome ~ group, data = data) ## ## ## Frequencies of Responses ## ## 1 2 3 4 5 6 7 8 9 10 ## 8 19 32 32 43 23 17 10 10 6 ##